Imidapril Dari Pharma

Imidapril, the active ingredient in Imidapril Dari Pharma, is an ACE inhibitor presented as an oral tablet for oral use. It is employed to manage high blood pressure and support treatment of heart failure in adult patients.

GNH USA supplies Imidapril Dari Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global logistics for regulated medicines.

Imidapril acts on the renin‑angiotensin system to lower blood pressure and improve cardiac function.

Hypertension: reduces systolic and diastolic blood pressure, helping prevent cardiovascular complications. Heart failure: decreases ventricular workload and improves symptoms such as dyspnea and fatigue.

Imidapril may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache. - Fatigue or general weakness. - Nausea or mild gastrointestinal upset. - Transient hypotension.

Serious or Rare Side Effects: - Angioedema: swelling of lips, tongue, or airway. - Severe neutropenia or leukopenia. - Hepatic dysfunction: elevated transaminases. - Acute renal impairment or failure. - Anaphylactic reactions. - Myocarditis or pericarditis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor key parameters. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte balance: monitor potassium levels, especially when combined with potassium‑sparing agents. - History of angioedema: avoid use in patients with prior episodes of swelling. - Pregnancy considerations: use only if the potential benefit justifies the potential risk to the fetus. - Store at below 25°C: keep in the original pack, protect from moisture.

Imidapril can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase renal risk. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - Dual blockade with ARBs or another ACE inhibitor: increases risk of hypotension and renal dysfunction.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment. - NSAIDs: can blunt antihypertensive response and affect renal function. - Lithium: may increase lithium levels, necessitating serum monitoring.